



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-063001	Application No. 10/086,217
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Mundy et al.	
		Filing Date February 21, 2002	Group Art Unit 1644

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BA	5,217,870	06/08/1993	Hession et al.			
	BB	5,272,263	12/21/1993	Hession et al.			
	BC	5,367,056	11/22/1994	Hession et al.			
	BD	5,695,755	12/09/1997	Papayannopoulou			
	BE	5,824,304	10/20/1998	Papayannopoulou			
	BF	5,843,438	12/01/1998	Papayannopoulou			
	BG	5,871,734	02/16/1999	Lobb et al.			
	BH	5,888,507	03/30/1999	Burkly			
	BI	5,932,214	08/03/1999	Lobb et al.			
	BJ	6,252,043	06/26/2001	Hession et al.			
	BK	6,307,025	10/23/2001	Hession et al.			
	BL	6,602,503	08/05/2003	Lobb et al.			
	BM						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	BN	WO 90/13300	11/15/1990	WIPO				
	BO	WO 93/13798	07/22/1993	WIPO				
	BP	WO 93/15764	08/19/1993	WIPO				
	BQ	WO 94/11027	05/26/1994	WIPO				
	BR	WO 94/16094	07/21/1994	WIPO				
	BS	WO 94/17828	08/18/1994	WIPO				
	BT							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	BU	Chevalier et al., "Interleukin-6 Family of Cytokines Induced Activation of Different Functional Sites Expressed by gp130 Transducing Protein," <i>J. Biol. Chem.</i> 271:14764-14772, 1996.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-063001	Application No. 10/086,217
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Mundy <i>et al.</i>	
		Filing Date February 21, 2002	Group Art Unit 1644
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BV	Hemler <i>et al.</i> , "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides," <i>J. Biol. Chem.</i> 262:11478-11485, 1987.
	BW	Mori <i>et al.</i> , "Anti- $\alpha 4$ integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis," <i>Blood</i> 104:2149-2154, 2004.
	BX	Pulido <i>et al.</i> , "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4," <i>J. Biol. Chem.</i> 266:10241-10245, 1991.
	BY	Sanchez-Madrid <i>et al.</i> , "VLA-3: A novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization," <i>Eur. J. Immunol.</i> 16:1343-1349, 1986.
	BZ	Schwabe <i>et al.</i> , "Differential Expression and Ligand-induced Modulation of the Human Interleukin-6 Receptor on Interleukin-6-responsive Cells," <i>J. Biol. Chem.</i> 269:7201-7209, 1994.

Examiner Signature /Maher Haddad/	Date Considered 03/06/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	